[ad_1]
Shares of Vaxart Inc.
VXRT, -0.71%
up 44% in trade before marketing Thursday, after the biotech company announced the results of a phase 2 trial that its oral flu vaccine would have yielded better results than the one from Sanofi
SNY, + 0.09%
SAN -1.09%
Fluzone. Sanofi shares, listed in the United States, fell 1.6% ahead of the opening. "These latest results show that our vaccine caused a significant expansion of α4β7 + receptor (β7 +) receptors in muing mucosal receptors to approximately 60% of all activated B cells, while Fluzone maintained that base levels of 20%, "said Scientific Director Sean Tucker. Wouter Latour, chief executive of Vaxart, said: "We believe this clearly differentiates our oral vaccines from conventional injectable vaccines, and strongly suggests that vaccines based on Vaxart's proprietary adjuvant system could be an optimal protection against mucosal pathogens, including some of the major pathogens, public health threats such as influenza, norovirus, RSV and many others. "The title has dropped 55.4% from the beginning of the year until Wednesday, while the iShares Nasdaq Biotechnology Fund
BWI + 0.74%
rebounded 13.6% and the S & P 500
SPX, + 0.07%
gained 9.4%.
Have the latest news sent to your inbox. Subscribe to free e-mails from the MarketWatch newsletter. Register here.
Source link
